Enabling precision oncology care
through data-driven insights

As a sponsor of the 2021 American Society of Clinical Oncology (ASCO) conference, Sema4 is proud to partner in the mission to conquer cancer with knowledge. Sema4 is a patient-centered health intelligence company dedicated to improving the diagnosis, treatment, and prevention of disease through data-driven insights. Our continued focus on delivering science-led solutions for personalized patient care can be seen in our latest research and in Sema4 Signal®,, our comprehensive data-driven precision oncology portfolio.


Are you involved in running clinical trials?


Download our latest Research Highlight to learn:


    • Why patient identification poses a significant challenge for clinical trial stakeholders


    • How to leverage AI platforms to improve clinical trial matching


    • Which clinical trial eligibility requirements are important for breast and lung cancer trials

View our other 2021 ASCO abstracts and recent publications


2021 ASCO Abstracts

        • Extracting longitudinal anticancer treatments at scale using deep natural language processing and temporal reasoning. >>


        • Analyzing treatment patterns and time to the next treatment in chronic lymphocytic leukemia real-world data using automated temporal phenotyping. >>


        • Continuous genomic monitoring of multiple myeloma patients to identify patients of high risk for poor prognosis. >>


        • Patterns and predictors of treatment in muscle-invasive bladder cancer (MIBC): A real-world study. >>


      • Comparative efficacy of docetaxel versus novel hormonal agent in de novo metastatic hormone-sensitive prostate cancer: Real-world data curated by deidentified chart abstraction. >>

Recent publications

      • Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers. Ayers, KL et al., 2021. The Oncologist
        – Read our blog article here to learn more about we used real-world data to investigate the impact of race and ethnicity on treatment response in aNSCLC

      • A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers. Ayers, KL et al., 2021. BMC Cancer


Sema4 Signal enables and advances precision oncology care, from prevention to treatment to remission


Sema4 Signal is a comprehensive portfolio of data-driven precision oncology solutions


Incorporates advanced analytics, digital tools, and exome-based genomic testing


Products and services can be leveraged individually or as part of a holistic solution to meet the specific needs of providers, patients, payors, and health systems


For Oncologists and Health Systems



Detection of hereditary cancer variants, delivered via the Sema4 Traversa™ genomic platform.
Learn more


Comprehensive molecular profiling insights to help providers identify therapies and clinical trials.
Learn more


Advanced natural language processing (NLP) tools, powered by our Centrellishealth intelligence platform. Learn more.


For Biopharma

Sema4 Signal can help research teams to find trial patients and generate data. We work with partners from pre-clinical through clinical trials and commercialization, leveraging Sema4 Signal WES/WTS. This test integrates tumor-normal matched WES with WTS to rapidly deliver the most comprehensive information about somatic and germline alterations across ~18,500 genes, in solid tumors and hematologic malignancies. Learn more here.


Stay Connected or Contact Us Today

Keep up to date with our news updates, exclusive events, and latest research and developments.
Kindly fill out the form below or feel free to call us at 833-486-6260.